Impact on patients’ daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).
Matti S. Aapro
Consultant or Advisory Role - Eisai; Helsinn Healthcare
Honoraria - Eisai; Helsinn Healthcare
Research Funding - Helsinn Healthcare
Giorgia Rossi
Employment or Leadership Position - Helsinn Healthcare
Giada Rizzi
Employment or Leadership Position - Helsinn Healthcare
Maria Elisa Borroni
Employment or Leadership Position - Helsinn Healthcare
Norman G. Nagl
Employment or Leadership Position - Eisai